We have also investigated whether the dual PI3K/mTOR inhibitors BEZ235 and GSK2126458, or the dual mTORC1/mTORC2 inhibitor (AZD8055), can sensitize everolimus resistant breast cancer cell lines to everolimus by reducing AKT phosphorylation. Here, PIK3CA is linked to breast carcinoma.